Proven Executive Leadership
BOARD AND KEY MANAGEMENT
The Board and Management team bring extensive experience across pharmaceutical development, clinical operations, and corporate strategy to guide the company’s growth and execution.
Dr David Foster
Managing Director and CEO
Dr. David Foster is an experienced biotechnology entrepreneur and public company executive with more than 20 years of experience founding, building and leading life sciences organizations.
Jason Carroll
Non-Executive Chair
Mr Carroll brings over 30 years of experience in the field of life sciences and has held senior leadership roles at several multinational pharmaceutical companies including Johnson & Johnson, Janssen Pharmaceutica and iNova Pharmaceuticals.
Chris Ntoumenopoulos
Non-Executive Director
Mr Ntoumenopoulos has more than 20 years’ financial markets experience and is the Managing Director at Twenty 1 Corporate, an Australian-based corporate advisory firm.
Cameron Jones
Chief Financial Officer & Company Secretary
Mr Jones is a qualified Chartered Accountant and registered tax agent with extensive experience acting as CFO, Company Secretary and transaction advisor for ASX-listed and venture capital investee companies.
Scientific Expertise Leadership
Island Fellows
The Island Fellows Team comprises leading experts who are actively engaged in advancing our clinical programs and who provide strategic guidance across clinical development, regulatory pathways, and scientific innovation.
Prof Stephen Thomas MD
Professor Thomas has an international leadership role as Lead Principal Investigator for Pfizer/BioNTech global Phase III COVID-19 vaccine trial now being deployed globally.
Prof. Thomas is a world-renowned virologist and vaccinologist and has authored numerous papers and articles on dengue fever, Zika and many other infectious diseases.
Prof. Thomas is a world-renowned virologist and vaccinologist and has authored numerous papers and articles on dengue fever, Zika and many other infectious diseases.
Raymond Taylor
Mr Taylor has over 40 years of experience in drug development, antiviral therapeutics, biodefence and regulatory strategy.
He spent 19 years in senior leadership roles at BioCryst Pharmaceuticals, where Galidesivir was originally developed. Mr Taylor has direct historical experience with Galidesivir, including antiviral development, program execution and regulatory initiatives.
He spent 19 years in senior leadership roles at BioCryst Pharmaceuticals, where Galidesivir was originally developed. Mr Taylor has direct historical experience with Galidesivir, including antiviral development, program execution and regulatory initiatives.
Experienced Industry Advisors
Strategic Advisors
Island Pharmaceuticals is supported by a highly experienced group of strategic advisors who provide independent expertise across drug development, clinical research, regulatory affairs, commercialisation and corporate strategy.
Dr Herbert Slade, MD
Chief Medical Advisor
Dr. Slade is a dual board-certified specialist in pediatrics and clinical immunology with more than 30 years of industry experience in clinical research and drug development. He has directed over 300 clinical trials of drugs, biologics and devices, and has more than 100 peer-reviewed publications.
Nick McCoy
Vice President Clinical Product Development
Nick is an experienced clinical research professional with a demonstrated history working in the pharmaceutical, biotechnology and medical device industries.
Dr Daniel Levy, PhD
Head of CMC
Dr Levy is an experienced organic and medicinal chemist with nearly 35 years in the biopharmaceutical industry, contributing to the design of novel therapeutics targeting cardiovascular disease, cancer, inflammatory and CNS disorders. His work is documented in almost 30 peer-reviewed publications and more than 40 issued or published United States patents.
Diana Goldman
Head of Quality
Diana Goldman has been serving as Quality and Regulatory Compliance advisor for over 150 biopharmaceutical companies including in roles as acting Head of Quality. Diana has been providing services for over 35 years to virtual and fully integrated small and medium-sized biopharmaceutical companies as appropriate to various phases of product development, from pre-IND through commercialisation.
Mark Herzog
Senior Global Health Advisor
Mr Herzog is a senior executive with more than 20 years of leadership across global health security, pharmaceutical business development, corporate communications and public policy in highly regulated life sciences environments.
Mari Heghinian
Director, Project Operations
Mari Heghinian, PhD, is an experienced drug development professional with expertise in program management and operational execution across biotechnology and pharmaceutical organisations.